Value of a new inflammatory parameter in malignant pleural mesothelioma prognosis

Öz

Objective: Malignant Pleural Mesothelioma (MPM) generally associated with asbestos exposure is a tumor with poor prognosis. Modified Glasgow Prognostic Score (GPS) which may be a prognostic parameter in patients with MPM is a designed based score including increased C-reactive protein (CRP) levels and decreased albumin .In this study we aimed to investigate the effect of GPS score on the prognosis of MPM and the role of other potential factors. Methods: In this retrospective planned study 140 histological diagnosed MPM patients were included. Results: Mean age of 140 MPM patients were 52.92 years (83 male and 57 female). A total of 91 patients had environmental asbestos exposure and exposure time was the 31 years. Symptoms of the patients started approximately 4.8 months before the application. The most frequently seen symptoms were in 125 patients dyspnea, in 94 patients chest pain and in 22 patients weight loss. GPS score of the patients were as follows; 64 patients two, 14 patients one, 22 patients zero. Of the patients, 112 died and 28 were alive. Mean survival time was 14 months. Patients with GPS score 2 lived for 10 months, GPS score 1 lived for 15 and GPS score 0 lived for 18 months. This difference was statistically significant. Furthermore, the male sex and age older than 65 years were found as poor prognostic parameters on the survival. Conclusion: A simple and inexpensive parameter able to be used to estimate the prognosis of MPM patients could not be developed .GPS score increases in inflammatory conditions. GPS is a simple and inexpensive parameter that can be used for detecting the severity of patients with MPM.

Anahtar Kelimeler

• Modified Glasgow Prognostic Score, Malignant Pleural Mesothelioma, Prognosis

Malign Plevral Mezotelyoma prognozunda yeni bir inflamatuar parametrenin değeri

Öz

Amaç: Malign Plevral Mezotelyoma (MPM) genel olarak asbest teması ile ilişkili ve kötü prognozlu bir tümördür. MPM hastalarında prognostik bir parametre olabilecek olan Modifiye Glasgow Prognoz Skoru (GPS), artmış C-Reaktif Protein (CRP) ve azalmış albümin düzeyleri temel alınarak hazırlanmış bir skordur. Bu çalışmada GPS skorunun MPM prognozu üzerindeki etkilerini incelemek ve diğer potansiyel etkenlerin rollerini araştırmak amaçlanmıştır. Yöntemler: Retrospektif planlanan bu çalışmaya histopatolojik olarak MPM tanısı konan 140 hasta alındı. Bulgular: Toplam 140 MPM hastasının ortalama yaşı 52,92 yıl idi (83 erkek ve 57 kadın) idi. Toplam 91 hastada çevresel asbest teması saptandı ve temas süresi ise 31 yıldı. Hastaların semptomları başvurudan yaklaşık olarak 4,8 ay önce başlamıştı. En sık saptanan semptomlar ise 125 hastada nefes darlığı, 94 hastada göğüs ağrısı ve 22 hastada kilo kaybıydı. GPS skor değeri olarak 64 hasta 2, 22 hasta 1 ve 14 hasta ise sıfır değerini almışlardır. Çalışmaya alınan hastaların 112\'si vefat etmiş ve 28\'i hayattaydı. Tüm hastaların ortalama yaşam süresi 14 ay idi. GPS skoru 2 olan hastalar 10 ay, 1 olanlar 15 ve sıfır olanlar ise yaklaşık 18 ay yaşamışlardır. Bu fark istatistikî olarak önemli bulunmuştur. Ayrıca erkek cinsiyet ve 65 yaş üstü olmada yaşam süresini kötü etkileyen parametreler olarak bulunmuştur. Sonuç: MPM hastalarının prognozunu tahminde kullanılabilecek basit ve ucuz bir parametre geliştirilememiştir. GPS skoru inflamatuar durumlarda artmaktadır. GPS skoru MPM hastalarının ciddiyetini tespitte kullanılabilecek basit ve ucuz bir parametre olarak görülmektedir.

Anahtar Kelimeler

• Modifiye Glasgow Prognoz Skoru, Malign Plevral Mezotelyoma, Prognoz

Kaynakça

1. Tanrikulu AC, Senyigit A, Dagli CE, et al. Environmental malignant pleural mesothelioma in SoutheastTurkey. Saudi Med J 2006;27:1605-1607.
2. Senyiğit A, Bayram H, Babayiğit C, et al. Malignant pleural mesothelioma caused by environmental exposure to asbes- tos in the Southeast of Turkey: CT findings in 117 patients. Respiration 2000;67:615-622.
3. Senyiğit A, Babayiğit C, Gökirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental as- bestos fiber exposure in the southeast of Turkey. Respira- tion 2000;67:610-614.
4. Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radio- graphic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respira- tion 2010;80:480-487.
5. Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin Oncol 1992;19:64- 71.
6. Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue poly- peptide antigen in malignant mesothelioma. Lung Cancer 1999;25:25-32.
7. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organi- zation for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-152.
8. Herndon JE, Green MR, Chahinian AP, et al. Factors pre- dictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia Group B. Chest 1998;113:723-731.

9. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
10. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic ef- fect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220- 5227.
11. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasi- bility, validity, and results of using the European Organi- zation for Research and Treatment of Cancer core quality of life questionnaire and lung cancer module. J Clin Oncol 2004;22:3172-3180.
12. Robinson BW, Musk AW, Lake RA. Malignant mesothe- lioma. Lancet 2005;366:397-408.
13. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation- based prognostic indices in malignant pleural mesothelio- ma. J Thorac Oncol 2012;7:587-594.
14. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic in- flammatory response in patients with inoperable non-small- cell lung cancer. Br J Cancer 2003;89:1028-1030.
15. Montanaro F, Rosato R, Gangemi M, et al. Survival of pleu- ral malignant mesothelioma in Italy: a population-based study. Int J Cancer 2009;124:194-200.
16. Edwards JG, Abrams KR, Leverment JN. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-735.
17. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Can- cer 1988;41:525-530.